BCL2 and acute myeloid leukemia: Recently, the choice of AML therapy in adults has divided into a decision between CC (most commonly cytosine arabinoside and an anthracycline, often combined with other agents), or therapy with a BCL-2 inhibitor (typically venetoclax) combined with a HMA (decitabine, azacytidine) (VH).